Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A more affordable option for HER2+ breast cancer patients just got the green light. The FDA has approved pertuzumab-qcay (Pebrilzo), a biosimilar to Perjeta, for use alongside trastuzumab in three settings: metastatic, neoadjuvant, and adjuvant therapy for high-risk early disease. The approval was based on analytical and pharmacokinetic data showing no meaningful differences from the reference drug.
A biosimilar alternative to Perjeta is now FDA-approved for HER2+ breast cancer
The FDA has approved pertuzumab-qcay (Pebrilzo), a biosimilar referencing pertuzumab (Perjeta), for combination use with trastuzumab (Herceptin) across three HER2-positive breast cancer settings: metastatic disease, neoadjuvant therapy, and adjuvant therapy for early-stage high-risk disease. Developed by Biocon Limited, it marks the company's fifth oncology biosimilar to receive FDA approval.
The approval was grounded in structural and functional analytical characterization, analytical similarity studies, and comparative pharmacokinetic data — with no clinically meaningful differences found in quality, safety, efficacy, or immunogenicity compared to the reference product. Notably, the European Medicines Agency's CHMP also issued a positive opinion for the drug in September 2026, making it the first monoclonal antibody biosimilar recommended under EMA's new tailored clinical development pathway, which allows approval without a dedicated comparative efficacy trial.
Key Takeaways
Why it matters: Biosimilars like Pebrilzo can significantly reduce treatment costs for HER2+ breast cancer patients, a population that often faces heavy financial burdens alongside their diagnosis — potentially expanding access to a proven, life-extending therapy.